Literature DB >> 9669075

Atticotomy with reconstruction for limited cholesteatoma.

D M East1.   

Abstract

Several authors have confirmed that it is entirely reasonable to perform a one-stage atticotomy for attic cholesteatomas which are limited in size. Over a period of 10 years, 195 primary procedures were performed for cholesteatoma, and, out of this total, 65 were operated on by an established technique of cartilage repair. In this group of a limited atticotomy there were only two recurrences (3%) and so the technique is considered reliable and, furthermore, using the author's modification, there is no need to dissect out perichondrial flaps. It is recommended that attic cholesteatomas are operated on while they are as small as possible--no damage to the hearing occurred in 63 (96.9%) of the ears in this series--as the results of ossicular repair in ears damaged by cholesteatoma are unpredictable, especially when there is eustachian tube dysfunction.

Entities:  

Mesh:

Year:  1998        PMID: 9669075     DOI: 10.1046/j.1365-2273.1998.00145.x

Source DB:  PubMed          Journal:  Clin Otolaryngol Allied Sci        ISSN: 0307-7772


  3 in total

1.  Management of epi- and mesotympanic cholesteatomas by one-stage trans-canal atticotomy in adults.

Authors:  Daniele Bernardeschi; Francesca Yoshie Russo; Yann Nguyen; Giuseppina Canu; Isabelle Mosnier; Daniele De Seta; Evelyne Ferrary; Olivier Sterkers
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-01-04       Impact factor: 2.503

2.  Cartilage tympanoplasty: postoperative functional results.

Authors:  Cyril Page; Laurent Charlet; Vladimir Strunski
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-02-28       Impact factor: 2.503

3.  Cost-comparison analysis of diffusion weighted magnetic resonance imaging (DWMRI) versus second look surgery for the detection of residual and recurrent cholesteatoma.

Authors:  David L Choi; Michael K Gupta; Ryan Rebello; Jason D Archibald
Journal:  J Otolaryngol Head Neck Surg       Date:  2019-11-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.